Considering that FAT3 and LRP1B genes lack hotspot mutations in lung adenocarcinoma, and these two genes may not even be included in the list of clinical routine gene testing (especially FAT3), we recommend that whole exon or even the whole gene level mutations of FAT3 and LRP1B should be comprehensively detected in clinical practice, which will provide more useful information for treatment options of lung adenocarcinoma. This evidence concerns the gene FAT3 and lung adenocarcinoma.